DSB1559 / Duke Street Bio - LARVOL DELTA

Profiling of PARP1-selective inhibitor DSB2455 in HR deficient and proficient cancer models as monotherapy and in combination (EORTC-NCI-AACR 2024) - "Furthermore, DSB2455 demonstrated excellent tolerability and superior anti-tumour efficacy over the first-generation PARP1/2 inhibitor olaparib when tested in combination with the HER2-directed and topoisomerase I inhibitor payload ADC, T-Dxd, in HRD CDX models. ConclusionsThese data demonstrate the potential for DSB2455 to improve treatment efficacy and support its clinical development both as monotherapy and as a chemo-sensitiser in combination with standard-of-care chemotherapy and targeted agents. The data also afford the opportunity to enable efficacy of DSB2455 in HR proficient settings, thus significantly expanding its therapeutic utility and patient reach."

Monotherapy • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • BRCA • HER-2 • PARP2

Investigating PARP1 selective inhibitor DSB1559 efficacy in BRCA1-associated triple negative breast cancer (AACR 2024) - "CellTiter-Glo and qPCR assays were used to examine DSB1559 effect on cell viability and STING activation, respectively. DSB1559 is a novel and potent PARP1 inhibitor which has superior selectivity for PARP1 compared to Olaparib and PARP1i AZD5305. Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy compared to Olaparib in a BRCA1-associated immune-competent TNBC model."

Clinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • PARP2 • STING